Clinical trials: HNSCC
Head and Neck Cancer
DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897988
- Testing
- gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Oral Cancer, Oral Squamous Cell Carcinoma
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
The study will include patients with oral cancer and healthy controls of both sexes. Subjects having any systemic diseases or other types of cancer will be excluded.
- Trial name
- NCT06031337
- Testing
- ELISA
- Where
- Egypt
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Radiation Toxicity
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy delivers thin beams of radiation of different strengths directly to the tumor from many angles.
- Conditions
- Head and Neck Cancer, Radiation Toxicity, Xerostomia
- Trial name
- NCT00081029
- Testing
- management of therapy complications, radiation therapy
- Where
- 9 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Royal Marsden NHS Foundation Trust
HNSCC
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04169074
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Oral Cavity Squamous Cell Carcinoma
Biofeedback Rehabilitation to Improve Speaking and Eating in Public
Tongue cancer requires resection and reconstruction that can leave patients disabled with respect to speaking and eating. Impairment of tongue function can have significant impact on social interaction and employment.
- Trial name
- Biofeedback (NCT03650699)
- Testing
- Electropalatography Biofeedback Training
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Oral Squamous Cell Carcinoma, Oral Epithelial Dysplasia
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma
Oral cancer represents the sixth most common cancer worldwide whilst in Pakistan it ranks the second most common cancer in either gender.
- Trial name
- OSCC (NCT01987934)
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Academy of Interdisciplinary Dental Education and Research
Head and Neck Cancer, Pain
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer
RATIONALE: Acupuncture may help relieve pain and dysfunction caused by cancer surgery. It is not yet known whether acupuncture is more effective than standard therapy in treating pain and dysfunction in patients who have…
- Trial name
- NCT00090337
- Testing
- acupuncture therapy, standard follow-up care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oral Cavity Squamous Cell Carcinoma, Saliva Altered
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
According to the World Health Organization, oral cancer (OC) is the eighth most common cancer in the world with a five year survival rate of 50%.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Saliva Altered, Precancerous Lesions
- Trial name
- OCSALTM (NCT03529604)
- Testing
- Saliva sampling, ELISA, HPLC
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Head and Neck Cancer
Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005088
- Testing
- cisplatin, radiation therapy
- Where
- 258 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Hepatitis C
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Compare Hepatiis C Virus (HCV) detection between oral squamous cell carcinoma (OSCC) and normal tissues, to determine the possible relationship between HCV and OSCC.
- Trial name
- NCT03109457
- Testing
- oral squamous cell carcinoma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Head and Neck Cancer, Head and Neck Carcinoma
FALCOn (Facteur AnthropoLogique Cancer Orl)
There are no studies on practitioner-related factors influencing decision-making in the field of carcinology of aerodigestive carcinomas.
- Trial name
- FALCOn (NCT03663985)
- Testing
- Groupe FALCOn
- Where
- France
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Institut Claudius Regaud
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
- Trial name
- NCT03524326
- Testing
- Lenvatinib Pill, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Squamous Cell
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
This is a prospective post-marketing surveillance (PMS) study to collect safety information from more than 600 subjects with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN) treated with Erbitux as…
- Trial name
- NCT01075841
- Testing
- Cetuximab
- Sponsor
- Merck KGaA, Darmstadt, Germany
Oral Squamous Cell Carcinoma (OSCC)
Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features
Oral squamous cell carcinoma is a major public health problem , especially in West Asian countries. Cyclin D1 accelerates cell cycle and thus may be implicated in uncontrolled cellular proliferation and tumor progression.
- Trial name
- NCT07778615
- Testing
- immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sections
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Sohag University
HNSCC, AI
10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
Introduction: The incidence of occult cervical lymph node metastases (OCLNM) is reported to be 20%-30% in early-stage oral cancer and oropharyngeal cancer.
- Conditions
- HNSCC, AI, Radiomic, MRI
- Trial name
- NCT06366906
- Testing
- The Resnet50 deep learning (DL) model
- Where
- 2 sites in China
- Volunteers
- 319 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oral Squamous Cell Carcinoma
Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities.
- Trial name
- OSCC (NCT05150509)
- Testing
- Oral Squamous Cell Carcinoma
- Where
- 2 sites in Bangladesh
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- DR. MALA KHAN